The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse A Single-centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four-period Crossover Study in Healthy Male Volunteers, to Assess the Effect on QT/QTc Interval of Single Oral Doses of AZD1981 (200 mg and 2000 mg) Using Moxifloxacin (Avelox®) as a Positive Control
- collapse An evaluation of efficacy and safety of corresponding doses of Pulmicort Turbuhaler and Pulmicort Respules in Japanese asthmatic adult patients (open, multicenter, phase III study)
- collapse A Phase 3, randomised, open-label, crossover study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthma
- collapse The use of a forecasting system for predicting exacerbations of COPD: effect on symptoms and hospitalisation and relevance of viral infections
- collapse A randomised, double-blind, placebo-controlled, two-way crossover, single-centre methodologhy study in healthy subjects to evaluate the effect of oral dosing with AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS
- collapse A Phase II, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Japanese Patients Who Have Systemic Lupus Erythematosus (SLE
- collapse Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
- collapse An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg
- collapse A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents
- collapse Patient perception of symptom variability. A cross-sectional study of patients with severe COPD.
